Abstract
Previous research has implicated vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic retinopathy (DR). Although many studies reviewed the use of anti-VEGF for diabetic macular oedema, little has been written about the use of anti-VEGF for proliferative diabetic retinopathy (PDR). This study is a review of relevant publications dealing with the use of anti-VEGF for the treatment of PDR. The articles were identified through systematic searches of PUBMED and the Cochrane Central Register of Controlled Trials. At the end of each section, we summarized the level of evidence of the scientific literature. Off-label use of anti-VEGF agents was found to be beneficial in PDR, especially in cases with neovascular glaucoma, persistent vitreous haemorrhage, and before vitrectomy. The disadvantages of the use of anti-VEGF are its short-effect duration, causing tractional retinal detachment in cases with pre-existing pre-retinal fibrosis and endophthalmitis in rare cases. There is no conclusive evidence from large randomized trials regarding the efficacy of anti-VEGF treatment in PDR. However, numerous case series, sound biochemical mechanism of action, and increasing experience with using anti-VEGF drugs can be used to support the ongoing use of this treatment modality in selected patients.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 2010; 304: 649–656.
The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976; 81: 383–396.
Fong DS, Aiello LP, Ferris FL 3rd, Klein R . Diabetic retinopathy. Diabetes Care 2004; 27: 2540–2553.
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO . Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1–29.
Abu El-Asrar AM, Nawaz MI, Kangave D, Mairaj Siddiquei M, Geboes K . Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res 2013; 2013: 539658.
Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E et al. Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198–1202.
Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006; 20: 1495–1497.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–1487.
Wang X, Wang G, Wang Y . Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2009; 148: 883–889.
Matsuoka M, Ogata N, Minamino K, Matsumura M . Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol 2006; 50: 116–120.
Abu El-Asrar AM, Missotten L, Geboes K . Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2007; 91: 822–826.
Lim JI, Spee C, Hinton DR . A comparison of hypoxia-inducible factor-α in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 2010; 30: 1472–1478.
Chung EJ, Kang SJ, Koo JS, Choi YJ, Grossniklaus HE, Koh HJ . Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J 2011; 52: 151–157.
Shibuya M . Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469–478.
The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. Int Ophthalmol Clin 1987; 27: 239–253.
Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB . Long-term stability and visual outcome after favourable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991; 98: 1575–1579.
Gentile RC, Stegman Z, Liebmann JM, Dayan AR, Tello C, Walsh JB et al. Risk factors for ciliochoroidal effusion after panretinal photocoagulation. Ophthalmology 1996; 103: 827–832.
McDonald HR, Schatz H . Macular edema following panretinal photocoagulation. Retina 1985; 5: 5–10.
Jardeleza MS, Miller JW . Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol 2009; 24: 87–92.
Marshall J . The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 2005; 32 (6 Suppl 9): S43–S47.
Abdallah W, Fawzi AA . Anti-VEGF therapy in proliferative diabetic retinopathy. Int Ophthalmol Clin 2009; 49: 95–107.
Hussain N, Ghanekar Y, Kaur I . The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol 2007; 55: 445–450.
Nguyen DH, Luo J, Zhang K, Zhang M . Current therapeutic approaches in neovascular age-related macular degeneration. Discov Med 2013; 15: 343–348.
NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. Accessed September 2012 . Available from http://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/stage_2_consultation_levels_and_grades.pdf.
Rizzo S, Genovesi-Ebert F, Bartolo E, Vento A, Miniaci S, Williams G . Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 837–842.
Chen E, Park CH . Use of intravitreal bevacizumab as preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26: 699–700.
Ishikawa K, Honda S, Tsukahara Y, Negi A . Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2009; 23: 108–111.
Mishahi A, Roohiport R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H . Bevacizumab augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18: 263–269.
Spaide RF, Fisher YL . Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275–278.
Arevalo JF, Garcia-Amaris RA . Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev 2009; 5: 39–46.
Avery RL . Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352–354.
Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695–1715.
Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M . Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina 2010; 30: 761–764.
Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M et alPan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema. The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116: 1488–1497.
Lee SJ, Koh HJ . Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther 2009; 25: 173–174.
Thew M . Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Clin Exp Optometry 2009; 92: 34–37.
Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M . Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1699–1705.
Mendrinos E, Donati G, Pournaras CJ . Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta Ophthalmol 2009; 87: 683–684.
Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M et alMacugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23–28.
Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E . Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008; 86: 683–687.
Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U . Repeated intravitreal bevacizumab treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol 2011; 89: 76–81.
Torres-Soriano ME, Reyna-Castelan E, Hernandez- Rojas M . Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy. Retinal Cases Brief Rep 2009; 3: 70–73.
Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH . Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29: 768–774.
Jonas JB, Schmidbauer M, Rensch F . Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol 2009; 87: 571–572.
Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Eid Farah M et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 213–216.
Jalil A, Fenerty C, Charles S . Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond) 2007; 21: 1541.
Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 2008; 3: e2675.
Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116: 927–938.
Krishnan R, Goverdhan S, Lochhead J . Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye (Lond) 2009; 23: 1238–1239.
Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R . Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009; 116: 1943–1948.
Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S et al. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: the 2010 GLADAOF lecture. J Ophthalmol 2011; 2011: 584238.
Goel N, Kumar V, Ghosh B . Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema. Int Ophthalmol 2011; 31: 39–42.
Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 2010; 30: 781–786.
Frenkel RE, Mani L, Toler AR, Frenkel MP . Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 2007; 143: 1034–1035.
Wu L, MartÃnez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et alPan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of IVB (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81–87.
Gandhi JS, Tan LT, Pearce I, Charles SJ . Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease. Eye 2009; 23: 742–743.
Mitamura Y, Ogata K, Oshitari T, Asaumi N, Yamamoto S . Retinal detachment with macular hole following intravitreal bevacizumab in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 717–718.
Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I . Safety of repeat intravitreal injections of IVB versus ranibizumab: our experience after 2,000 injections. Retina 2009; 29: 313–318.
Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53–67.
Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 2008; 3: e3554.
D’Amore PA . Vascular endothelial cell growth factor-A: not just for endothelial cells anymore. Am J Pathol 2007; 171: 14–18.
Maharaj AS, D’Amore PA . Roles for VEGF in the adult. Microvasc Res 2007; 74: 100–113.
Fagan XJ, Al-Qureshi S . Intravitreal injections: a review of the evidence for best practice. Clin Exp Ophthalmol 2013; 41: 500–507.
Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A et al. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating short term effects of intravitreal Ranibizumab or Triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011; 31: 1009–1027.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et alMARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
CATT Research Group Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–2816.
Roth DB, King A, Weiss M, Klein D . Systemic adverse events after bevacizumab. Ophthalmology 2009; 116: 1226.
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L et alRIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013–2022.
D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR et al. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age related macular degeneration. Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992–1001.
Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92: 1606–1611.
Campbell RJ, Bell CM, Campbell Ede L, Gill SS . Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Curr Opin Ophthalmol 2013; 24: 197–204.
Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR . Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol 2008; 66: 667–673.
Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S . Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008; 18: 255–262.
Lim TH, Bae SH, Cho YJ, Lee JH, Kim HK, Sohn YH . Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol 2009; 23: 188–192.
Eid TM, Radwan A, el-Manawy W, el-Hawary I . Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol 2009; 44: 451–456.
Jonas BJ, Libondi T, Baltz S, Vossmerbaeumer U . Intravitreal bevacizumab for vitreous haemorrhage. Acta Ophthalmol 2008; 86: 585–586.
Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM . Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009; 29: 1134–1140.
Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013; 131: 283–293.
Krzystolik MG, Filippopoulos T, Ducharme JF, Loewenstein JI . Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy. Arch Ophthalmol 2006; 124: 920–921.
Smith JM, Steel DH . Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2011; (5): CD008214.
Ahn J, Woo SJ, Chung H, Park KH . The effect of adjunctive intravitreal bevacizumab for preventing post vitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011; 118: 2218–2226.
Zhao LQ, Zhu H, Zhao PQ, Hu YQA . Systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011; 95: 1216–1222.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98 (5 Suppl): 766–785.
Myers SM . Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol 1980; 90: 210–216.
McDonald HR, Schatz H . Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1985; 92: 388–393.
Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M . Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003; 110: 2386–2394.
Filho JA, Messias A, Almeida FP, Ribeiro JA, Costa RA, Scott IU et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol 2011; 89: 567–572.
Cho WB, Oh SB, Moon JW, Kim HC . Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009; 29: 516–522.
Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3rd . Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992; 99: 1351–1357.
Erdol H, Turk A, Akyol N, Imamoglu HI . The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina 2010; 30: 570–577.
Cintra LP, Costa RA, Ribeiro JA, Calucci D, Scott IU, Messias A et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study): 1-year results. Retina 2013; 33: 1109–1116.
Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU . Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (Ibepe study). Retina 2006; 26: 1006–1013.
Yang CM, Yeh PT, Yang CH, Chen MS . Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008; 146: 211–217.
Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R . Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86: 385–389.
Mason JO, Yunker JJ, Vail R, McGwin G Jr . Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008; 28: 1319–1324.
Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ et al. The DA VINCI study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118: 1819–1826.
Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM et alDA VINCI Study Group. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658–1665.
Clinicaltrials.gov. Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for DME. ClinicalTrial.gov Identifier NCT01627249 http://clinicaltrials.gov/ct2/show/NCT01627249. Accessed 15 October 2012. II.
Prompt Panretinal Photocoagulation Versus Ranibizumab plus Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol S) http://clinicaltrials.gov/show/NCT01489189. Accessed on 24 May 2013.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Osaadon, P., Fagan, X., Lifshitz, T. et al. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye 28, 510–520 (2014). https://doi.org/10.1038/eye.2014.13
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2014.13
Keywords
This article is cited by
-
Long-term efficacy and complications of intravitreal anti-vascular endothelial growth factor agents combined with ablative therapies in juvenile Coats disease: a five year follow-up study
Graefe's Archive for Clinical and Experimental Ophthalmology (2024)
-
Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea
BMC Health Services Research (2023)
-
Predictive factors for microvascular recovery after treatments for diabetic retinopathy
BMC Ophthalmology (2023)
-
Targeting angiogenesis in oncology, ophthalmology and beyond
Nature Reviews Drug Discovery (2023)
-
The stress-responsive protein REDD1 and its pathophysiological functions
Experimental & Molecular Medicine (2023)
